SI
SI
discoversearch

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor.  We ask that you disable ad blocking while on Silicon Investor in the best interests of our community.  If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.
Biotech / Medical : TITAN PHARMACEUTICAL (TTP)
 Public ReplyPrvt ReplyMark as Last ReadFilePrevious 10Next 10PreviousNext  
To: kenhott who wrote (350)12/7/2006 4:03:14 PM
From: DewDiligence_on_SI   of 362
 
If the safety profile is very clean (apart from the QT stuff), Iloperidone ought to have a chance to garner some respectable market share for patients who can’t tolerate the side effects of the most efficacious drugs (Zyprexa, Seroquel, and Risperdal). However, I don’t think Iloperidone has the efficacy to compete effectively for first-line treatment, so it’s unlikely that it will be a bona fide blockbuster.
Report TOU ViolationShare This Post
 Public ReplyPrvt ReplyMark as Last ReadFilePrevious 10Next 10PreviousNext  

HomeMailHotSubjectMarksPeopleMarksKeepersSettings
Terms Of UseContact UsCopyright/IP PolicyPrivacy PolicyAbout UsFAQAdvertise on SI
© 2025 Knight Sac Media.  Data provided by Twelve Data, Alpha Vantage, and CityFALCON News